Affiliation:
1. Department of Pharmacy , Faculty of Science, Noakhali Science and Technology University , Noakhali , Bangladesh
Abstract
Abstract
Notwithstanding, proton pump inhibitors (PPIs) are one of the most excellent options for different anti-secretory therapy in terms of improved symptomatic outcomes, numerous epidemiological and cohort studies provide evidence of an association between long-term proton PPIs use and increased fracture risk among users. The present attempt aimed to summarize the effect of long-term use of PPIs on musculoskeletal systems by considering the recent claims of different research groups to understand the risk of osteopenia and osteoporosis and to determine the risk factors associated with these complications. We extracted data from various systematic reviews and meta-analyses, cross-sectional studies, prospective studies, case-control studies, cohort studies, and in-vivo and in-vitro studies to observe the consequence of long-term PPIs uses over the patient’s bone health. Recent findings suggested that long-term use of PPIs plays an introductory and cabalistic role in the development of osteoporosis mostly hip fractures by disturbing numerous biological pathways and thus able to set up a link between over-prescription of PPIs and bone loss. Frequent administration of PPIs is associated with a significantly worse outcome to bone mineral density (BMD) profile and produce a negative impression on bone health. Since, there are limited data to determine the association of PPIs use and change in BMD, recommending further studies to find out this dissertation.
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference89 articles.
1. Farrell, B, Pottie, K, Thompson, W, Boghossian, T, Pizzola, L, Rashid, FJ, et al.. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician 2017;63:354–64.
2. Schubert, ML, Peura, DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842–60. https://doi.org/10.1053/j.gastro.2008.05.021.
3. Shin, JM, Kim, N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25–35. https://doi.org/10.5056/jnm.2013.19.1.25.
4. Vakil, N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437–45. https://doi.org/10.1136/bmj.e4558.
5. Richards, JB, Goltzman, D. Proton pump inhibitors: balancing the benefits and potential fracture risks. Can Med Assoc J 2008;179:306–7. https://doi.org/10.1503/cmaj.080873.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献